Promising Prospects for Alumis Inc.’s TYK2 Inhibitor A-005: Analyst Reiterates Buy Rating with $19 Price Target

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price target of $19.00.

Mitchell Kapoor has given his Buy rating due to a combination of factors related to Alumis Inc.’s promising developments in their TYK2 inhibitor, A-005. The preclinical data presented at the ACTRIMS conference demonstrated that A-005 achieved complete disease suppression in a mouse model of multiple sclerosis, indicating its potential efficacy in treating the disease.
Furthermore, A-005 has shown a clean pharmacokinetic profile with no serious side effects, and its ability to penetrate the blood-brain barrier in humans adds credibility to its potential effectiveness in the central nervous system. These factors, along with the planned Phase 2 proof-of-concept study in 2025, suggest that A-005 could enhance Alumis’s valuation if its preclinical success translates into clinical outcomes. Kapoor’s confidence in A-005’s prospects is reflected in the reiterated Buy rating and a 12-month price target of $19.

Kapoor covers the Healthcare sector, focusing on stocks such as Halozyme, Sarepta Therapeutics, and Summit Therapeutics. According to TipRanks, Kapoor has an average return of -19.9% and a 28.76% success rate on recommended stocks.